A Study to Evaluate the Safety and Efficacy of JNJ-64565111 in Non-diabetic Severely Obese Participants


The purpose of this study is to assess the effects of JNJ-64565111 compared with placebo after 26 weeks of treatment on the percent change in body weight from baseline and to assess the safety and tolerability, in non-diabetic severely obese participants.

Study Start Date

March, 26 2018

Estimated Completion Date

March 2019


  • Drug: JNJ-64565111 Dose Level 2
  • Drug: JNJ-64565111 Dose Level 3
  • Drug: Liraglutide
  • Drug: Placebo
  • Drug: JNJ-64565111 Dose Level 1

Study ID

Janssen Research & Development, LLC -- CR108314



Trial ID


Study Type


Trial Phase

Phase 2

Enrollment Quota



Janssen Research & Development, LLC

Inclusion Criteria

  • Body mass index (BMI) greater than or equal to (>=) 35 to less than or equal to (<=) 50 kilogram per square meter (kg/m^2) at the screening visit
  • Stable weight (that is, change of <= 5 percent [%] within 12 weeks before screening based on medical history)
  • Women must be either: (a) Postmenopausal, or (b) Permanently sterilized or otherwise be incapable of pregnancy, or (c) Heterosexually active and practicing a highly effective method of birth control, or (d) Not heterosexually active
  • Woman of childbearing potential have a negative pregnancy test at screening
  • Willing and able to adhere to specific the prohibitions and restrictions

Exclusion Criteria

  • History of obesity with a known secondary cause (for example, Cushing's disease/syndrome)
  • History of Type 1 diabetes mellitus, Type 2 diabetes mellitus (T2DM), diabetic ketoacidosis (DKA), pancreas or beta-cell transplantation, or diabetes secondary to pancreatitis or pancreatectomy
  • Has a Hemoglobin A1c (HbA1c) of >= 6.5% or fasting plasma glucose (FPG) >= 126 milligrams per deciliter (mg/dL) (>= 7.0 millimoles per liter [mmol/L]) at screening
  • Screening calcitonin of >= 50 picograms per milliliter (pg/mL) personal history or family history of medullary thyroid cancer, or of multiple endocrine neoplasia syndrome type 2 (MEN 2), regardless of time prior to screening
  • History of glucagonoma




18 Years to 70 Years

Accepts Healthy Volunteers


Study Locations and Contact Information (16)

Study Location Distance Name Phone Email
Milford Emergency Associates Inc - Marlborough, Massachusetts 22.9 miles None None None
Omega Medical Research - Warwick, Rhode Island 49.1 miles None None None
Weill Cornell Medicine - New York, New York 187.1 miles None None None
Central New York Clinical Research - Manlius, New York 251.6 miles None None None
Rapid Medical Research - Cleveland, Ohio 539.9 miles None None None
Coastal Carolina Research Center - Mount Pleasant, South Carolina 815.9 miles None None None
LMarc Research Center - Louisville, Kentucky 823.4 miles None None None
Allegiance Reserach Specialists LLC - Wauwatosa, Wisconsin 862.1 miles None None None
Medisphere Medical Research Center Llc - Evansville, Indiana 919.4 miles None None None
Care Partners Clinical Research - Jacksonville, Florida 1,014.6 miles None None None
Dallas Diabetes Research Center - Dallas, Texas 1,546.2 miles None None None
Permian Research Foundation - Odessa, Texas 1,860.2 miles None None None
Advanced Clinical Research - Boise, Idaho 2,268.1 miles None None None
Central Phoenix Medical Clinic - Phoenix, Arizona 2,294.3 miles None None None
Rainier Clinical Research Center - Renton, Washington 2,485.2 miles None None None
Diablo Clinical Research Inc - Walnut Creek, California 2,673.8 miles None None None

ClinicalTrialsLocator.com provides clinical trial listings in an easy to view format. All clinical trial information is pulled directly from ClinicalTrials.gov. This website does not guarantee acceptance into any clinical trial, and is not responsible for adverse events that may be incurred from a clinical trial.